Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Prostate Cancer

  Free Subscription


2 AJR Am J Roentgenol
1 Anticancer Res
3 BMC Cancer
1 Br J Radiol
1 Cancer Imaging
1 Clin Cancer Res
3 Eur J Radiol
3 Eur Radiol
3 Eur Urol
4 Int J Radiat Oncol Biol Phys
1 J Magn Reson Imaging
1 J Nucl Med
5 J Urol
1 Nat Rev Urol
2 Oncogene
1 PLoS One
1 Prostate
2 Radiology

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    AJR Am J Roentgenol

  1. CHANG SD, Margolis DJA, Turkbey B, Arnold AA, et al
    Practice Patterns and Challenges of Performing and Interpreting Prostate MRI: A Survey by the Society of Abdominal Radiology Prostate Disease-Focused Panel.
    AJR Am J Roentgenol. 2021 Feb 10:1-8. doi: 10.2214/AJR.20.23256.
    PubMed         Abstract available

  2. GIGANTI F, Kirkham A, Allen C, Punwani S, et al
    Update on multiparametric prostate MRI during active surveillance: current and future trends and role of the PRECISE recommendations.
    AJR Am J Roentgenol. 2020 Jul 29. doi: 10.2214/AJR.20.23985.
    PubMed         Abstract available

    Anticancer Res

  3. NIEDER C, Mannsaker B, Yobuta R
    Independent Validation of a Comprehensive Machine Learning Approach Predicting Survival After Radiotherapy for Bone Metastases.
    Anticancer Res. 2021;41:1471-1474.
    PubMed         Abstract available

    BMC Cancer

  4. WATANABE D, Kimura T, Watanabe K, Takano H, et al
    Effects of once-yearly zoledronic acid on bone density and incident vertebral fractures in nonmetastatic castration-sensitive prostate cancer patients with osteoporosis.
    BMC Cancer. 2021;21:422.
    PubMed         Abstract available

  5. LIN H, Liu Q, Zeng X, Yu W, et al
    Pembrolizumab with or without enzalutamide in selected populations of men with previously untreated metastatic castration-resistant prostate cancer harbouring programmed cell death ligand-1 staining: a retrospective study.
    BMC Cancer. 2021;21:399.
    PubMed         Abstract available

  6. NGUYEN HTN, Xue H, Firlej V, Ponty Y, et al
    Reference-free transcriptome signatures for prostate cancer prognosis.
    BMC Cancer. 2021;21:394.
    PubMed         Abstract available

    Br J Radiol

  7. KUO YH, Liang JA, Chen GH, Li CC, et al
    Safety of image-guided radiotherapy in definitive radiotherapy for localized prostate cancer: a population-based analysis.
    Br J Radiol. 2021 Apr 16:20200456. doi: 10.1259/bjr.20200456.
    PubMed         Abstract available

    Cancer Imaging

  8. OSMAN MM, Iravani A, Hofman MS, Hicks RJ, et al
    Intra-patient comparison of physiologic (68)Ga-PSMA-11 and (18)F-DCFPyL PET/CT uptake in ganglia in prostate cancer patients: a pictorial essay.
    Cancer Imaging. 2021;21:35.
    PubMed         Abstract available

    Clin Cancer Res

  9. MCKAY RR, Kwak L, Crowdis J, Sperger JM, et al
    Phase 2 multicenter study of enzalutamide in metastatic castration resistant prostate cancer to identify mechanisms driving resistance.
    Clin Cancer Res. 2021 Apr 13. pii: 1078-0432.CCR-20-4616.
    PubMed         Abstract available

    Eur J Radiol

  10. GASSENMAIER S, Afat S, Nickel D, Mostapha M, et al
    Deep learning-accelerated T2-weighted imaging of the prostate: Reduction of acquisition time and improvement of image quality.
    Eur J Radiol. 2021;137:109600.
    PubMed         Abstract available

  11. REGIS L, Salazar A, Planas J, Celma A, et al
    The position of urethrovesical anastomosis after robotic radical prostatectomy assessed by MRI predicts early functional recovery: A cohort analyses from a randomized clinical trial.
    Eur J Radiol. 2021;137:109589.
    PubMed         Abstract available

  12. TAKAHASHI H, Froemming AT, Bruining DH, Karnes RJ, et al
    Prostate MRI characteristics in patients with inflammatory bowel disease.
    Eur J Radiol. 2021;135:109503.
    PubMed         Abstract available

    Eur Radiol

  13. ALBERTS I, Hunermund JN, Sachpekidis C, Mingels C, et al
    The influence of digital PET/CT on diagnostic certainty and interrater reliability in [(68)Ga]Ga-PSMA-11 PET/CT for recurrent prostate cancer.
    Eur Radiol. 2021 Apr 15. pii: 10.1007/s00330-021-07870.
    PubMed         Abstract available

  14. SCHELB P, Wang X, Radtke JP, Wiesenfarth M, et al
    Simulated clinical deployment of fully automatic deep learning for clinical prostate MRI assessment.
    Eur Radiol. 2021;31:302-313.
    PubMed         Abstract available

  15. STEINBERG RL, Rasmussen RG, Johnson BA, Ghandour R, et al
    Prospective performance of clear cell likelihood scores (ccLS) in renal masses evaluated with multiparametric magnetic resonance imaging.
    Eur Radiol. 2021;31:314-324.
    PubMed         Abstract available

    Eur Urol

  16. CHU CE, Alshalalfa M, Sjostrom M, Zhao SG, et al
    Prostate-specific Membrane Antigen and Fluciclovine Transporter Genes are Associated with Variable Clinical Features and Molecular Subtypes of Primary Prostate Cancer.
    Eur Urol. 2021 Apr 8. pii: S0302-2838(21)00215.
    PubMed         Abstract available

  17. SADAGHIANI MS, Sheikhbahaei S, Werner RA, Pienta KJ, et al
    A Systematic Review and Meta-analysis of the Effectiveness and Toxicities of Lutetium-177-labeled Prostate-specific Membrane Antigen-targeted Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer.
    Eur Urol. 2021 Apr 8. pii: S0302-2838(21)00175.
    PubMed         Abstract available

  18. PIAZZA P, Rosiello G, Chacon VT, Puliatti S, et al
    Robot-assisted Cystectomy with Intracorporeal Urinary Diversion After Pelvic Irradiation for Prostate Cancer: Technique and Results from a Single High-volume Center.
    Eur Urol. 2021 Apr 7. pii: S0302-2838(21)00229.
    PubMed         Abstract available

    Int J Radiat Oncol Biol Phys

  19. SHI J, Xu K, Keyvanloo A, Udayakumar TS, et al
    A Multimodality Image Guided Precision Radiation Research Platform: Integrating X-ray, Bioluminescence, and Fluorescence Tomography With Radiation Therapy.
    Int J Radiat Oncol Biol Phys. 2020;108:1063-1072.
    PubMed         Abstract available

  20. TABRIZI S, Alshalalfa M, Mahal BA, Davicioni E, et al
    Doublecortin Expression in Prostate Adenocarcinoma and Neuroendocrine Tumors.
    Int J Radiat Oncol Biol Phys. 2020;108:936-940.
    PubMed         Abstract available

  21. MASTERS SC, Hofling AA, Gorovets A, Marzella L, et al
    FDA Approves Ga 68 PSMA-11 for Prostate Cancer Imaging.
    Int J Radiat Oncol Biol Phys. 2021 Apr 12. pii: S0360-3016(21)00357.

  22. MARCELLO M, Denham JW, Kennedy A, Haworth A, et al
    Reduced Dose Posterior to Prostate Correlates With Increased PSA Progression in Voxel-Based Analysis of 3 Randomized Phase 3 Trials.
    Int J Radiat Oncol Biol Phys. 2020;108:1304-1318.
    PubMed         Abstract available

    J Magn Reson Imaging

  23. ZHANG H, Li X, Zhang Y, Huang C, et al
    Diagnostic nomogram based on intralesional and perilesional radiomics features and clinical factors of clinically significant prostate cancer.
    J Magn Reson Imaging. 2021;53:1550-1558.
    PubMed         Abstract available

    J Nucl Med

  24. BRAVI CA, Fossati N, Gandaglia G, Suardi N, et al
    The importance of an adequate surgical template during salvage lymph node dissection for node-recurrent prostate cancer.
    J Nucl Med. 2021 Apr 16. pii: jnumed.121.262104. doi: 10.2967/jnumed.121.262104.

    J Urol

  25. FEUER Z, Meng X, Rosenkrantz AB, Kasivisvanathan V, et al
    Application of the PRECISION Trial Biopsy Strategy to a Contemporary Magnetic Resonance Imaging-Targeted Biopsy Cohort-How Many Clinically Significant Prostate Cancers are Missed?
    J Urol. 2021;205:740-747.
    PubMed         Abstract available

  26. BABAJIDE R, Carbunaru S, Nettey OS, Watson KS, et al
    Performance of Prostate Health Index in Biopsy Naive Black Men.
    J Urol. 2021;205:718-724.
    PubMed         Abstract available

  27. UMARI P, Eden C, Cahill D, Rizzo M, et al
    Retzius-Sparing versus Standard Robot-Assisted Radical Prostatectomy: A Comparative Prospective Study of Nearly 500 Patients.
    J Urol. 2021;205:780-790.
    PubMed         Abstract available

  28. TOSOIAN JJ, Trock BJ, Morgan TM, Salami SS, et al
    Use of the MyProstateScore Test to Rule Out Clinically Significant Cancer: Validation of a Straightforward Clinical Testing Approach.
    J Urol. 2021;205:732-739.
    PubMed         Abstract available

  29. MENG X, Chao B, Chen F, Huang R, et al
    Followup of Men with PI-RADS 4 or 5 Abnormality on Prostate Magnetic Resonance Imaging and Nonmalignant Pathological Findings on Initial Targeted Prostate Biopsy.
    J Urol. 2021;205:748-754.
    PubMed         Abstract available

    Nat Rev Urol

  30. ARCOT R, Polascik TJ
    Does MRI-guided TULSA provide a targeted approach to ablation?
    Nat Rev Urol. 2021;18:5-6.


  31. KWON OJ, Zhang L, Jia D, Xin L, et al
    Sox2 is necessary for androgen ablation-induced neuroendocrine differentiation from Pten null Sca-1(+) prostate luminal cells.
    Oncogene. 2021;40:203-214.
    PubMed         Abstract available

  32. WATSON MJ, Berger PL, Banerjee K, Frank SB, et al
    Aberrant CREB1 activation in prostate cancer disrupts normal prostate luminal cell differentiation.
    Oncogene. 2021 Apr 12. pii: 10.1038/s41388-021-01772.
    PubMed         Abstract available

    PLoS One

  33. KHAIRNAR R, Pugh SL, Sandler HM, Lee WR, et al
    Mapping expanded prostate cancer index composite to EQ5D utilities to inform economic evaluations in prostate cancer: Secondary analysis of NRG/RTOG 0415.
    PLoS One. 2021;16:e0249123.
    PubMed         Abstract available


  34. BAZZI LA, Sigurdardottir LG, Sigurdsson S, Valdimarsdottir U, et al
    Exploratory assessment of pineal gland volume, composition, and urinary 6-sulfatoxymelatonin levels on prostate cancer risk.
    Prostate. 2021 Apr 16. doi: 10.1002/pros.24130.
    PubMed         Abstract available


  35. TEMPANY-AFDHAL CMC, Padhani A, Barentsz J, Weinreb J, et al
    Perspectives and Concerns about PI-RADS and Variability.
    Radiology. 2021;298:E112.

  36. HARMON SA, Gesztes W, Young D, Mehralivand S, et al
    Prognostic Features of Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy Based on Multiparametric MRI and Immunohistochemistry Analysis of MRI-guided Biopsy Specimens.
    Radiology. 2021 Apr 13:202425. doi: 10.1148/radiol.2021202425.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.